Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. reported Q2 2026 results and outlined pipeline priorities in precision dermatology, cosmetics and biotechnology applications. Preclinical data from ATR-COSF showed repeat-dose delivery and anti-wrinkle activity in ex vivo human skin, supporting a planned human cosmetic application study starting in Q3 2026. The company continued enrolling the first cohort in its Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash, with topline data from the first cohort expected in Q4 2026, and advanced a recombinant protein portfolio including TEV Protease and T7 RNA Polymerase. Azitra plans to strategically pause further enrollment in the Phase 1b study of ATR-12 for Netherton syndrome to focus capital on programs with nearer-term opportunities. For Q2 2026, R&D expenses were $1.4 million, G&A expenses were $2.1 million, and net loss was $3.3 million versus $2.9 million a year earlier. As of June 30, 2026, cash and cash equivalents were $6.7 million and total stockholders’ equity was $7.3 million.
Azitra, Inc. is a pre-commercial synthetic biology company developing precision dermatology therapies using engineered microbes and proteins. For the six months ended June 30, 2026, it reported a net loss of $7.27 million, with operating expenses of $7.35 million and no product revenue. Operating cash use was $5.77 million, reflecting ongoing R&D and G&A spending.
Cash and cash equivalents rose to $6.73 million from $2.07 million at year-end 2025, driven mainly by a $10.4 million Series A preferred financing, warrant exercises and draws on an Equity Line of Credit, bringing total assets to $8.92 million and stockholders’ equity to $7.33 million. Shares outstanding increased to 60,603,742, and warrants outstanding reached 219,470,313, indicating significant potential dilution. Management discloses substantial doubt about the company’s ability to continue as a going concern over the next 12 months, citing cumulative losses of about $75.8 million and the need for additional financing despite current cash and access to approximately $13.8 million remaining under the Equity Line of Credit. Azitra also notes that its current equity level exceeds NYSE American minimums, though it remains under an exchange compliance plan.
Azitra, Inc. reported new ex vivo human skin data for its ATR-COSF program, a supernatant-based formulation containing recombinant human filaggrin (rHDfilaggrin). Repeat dosing of a 2% lyophilized supernatant hydrogel increased rHDfilaggrin penetration from the stratum corneum into the stratum granulosum compared with prior single-dose work, in a model using TH2-stimulated healthy skin explants.
In a second ex vivo model with defatted human skin, hydrogels containing the lyophilized supernatant increased elasticity in a dose-dependent manner. Formulations with 0.09% w/w and 7.5% w/w active ingredient produced about 1.6-fold and 4.4-fold elasticity enhancements, respectively, while around 0.28% w/w restored elasticity to values historically observed in healthy skin. A 0.3% w/w formulation produced approximately twice the elasticity of placebo. Standardized testing described the 2% formulation as non-irritating and non-corrosive to skin and eyes.
Azitra positions ATR-COSF as a high value cosmetic ingredient candidate and highlights a broader pipeline including ATR-04, an investigational live biotherapeutic for EGFR inhibitor–associated rash, which impacts approximately 150,000 people in the U.S.
Azitra, Inc. disclosure: Dauntless Investment Group, LLC filed a Schedule 13G reporting beneficial ownership of 5,804,636 shares of Azitra common stock, representing 9.58% of the class. The filer reports sole dispositive power over these shares and no voting power. The filing lists the filer as a "Single Family Office/Passive Investor" and is signed by the company's CFO on 06/25/2026.
Azitra, Inc.’s President and Chief Executive Officer, Francisco D. Salva, filed a Schedule 13D reporting a significant personal stake in the company. As of June 24, 2026, he beneficially owned 5,421,039 shares of common stock, representing 9.99% of the 52,907,666 shares outstanding.
His beneficial ownership includes 22,241 Incentive Stock Options and 1,334,748 shares underlying warrants that are exercisable within 60 days. It excludes 6,793,352 warrant shares that are not issuable within 60 days and are subject to a beneficial ownership limitation. Salva states he holds the securities for investment purposes but may buy or sell more shares depending on conditions.
Azitra, Inc. ownership disclosure: Stonepine entities and Jon M. Plexico report shared beneficial ownership of 1,744,339 shares of Common Stock, representing 9.9% of the class. The filing states the percentage "is giving effect to the 9.99% beneficial ownership limitation" and uses May 12, 2026 as the outstanding-share anchor of 16,192,438 shares.
The reporting persons note their holdings comprise 475,923 shares of Common Stock, Series A Preferred convertible into 27,107,210 shares, and Warrants to acquire 54,214,420 shares, each subject to a 9.99% beneficial ownership cap. Signatures show Jon M. Plexico as the reporting signatory.
Azitra, Inc. President and CEO Francisco D. Salva converted preferred stock into common shares. On June 16, 2026, he converted 500 shares of Series A Convertible Non-Redeemable Preferred Stock into 4,064,050 shares of common stock for no additional consideration, as provided in the Series A Certificate of Designations and subject to Beneficial Ownership Limitations. Following the automatic conversion, his reported beneficial ownership is 4,086,291 shares of common stock, which includes 22,241 incentive stock options exercisable within 60 days of June 16, 2026.
Azitra, Inc. filed a current report highlighting a CEO letter that outlines a strategic reorientation and growth plan for 2026 and beyond. The company completed a March financing of $10.5 million plus up to $21 million from warrant exercises, enabling expansion beyond therapeutics.
New initiatives include ATR-COSF, a recombinant filaggrin cosmetic ingredient targeting fine lines and wrinkles, with a clinical study expected to complete in late 2026 and potential partnering or commercialization as soon as 2027. Azitra is also launching recombinant protein programs using in-licensed microbial engineering technologies, initially focused on TEV protease and T7 RNA polymerase for research and manufacturing markets.
Within its existing pipeline, the company continues enrolling patients in ATR-04 for EGFR inhibitor-associated rash and added MD Anderson Cancer Center as a clinical site. Azitra plans to pause further enrollment in its ATR-12 Netherton syndrome trial to conserve capital and redirect funds to nearer-term cosmetic initiatives, emphasizing financial discipline and multiple potential paths to long-term value creation.
Azitra, Inc. reported results from its 2026 annual stockholder meeting and a major change to its charter. The company filed a certificate of amendment in Delaware to raise its authorized common stock from 200,000,000 to 750,000,000 shares, increasing overall authorized capital.
Stockholders elected four directors and authorized the board to implement one or more reverse stock splits. They also approved NYSE American–required approvals for potential issuances above 19.99% of outstanding common stock tied to a November 2025 securities purchase agreement with Alumni Capital LP and a March 18, 2026 financing involving Series A Preferred Stock and Series B and C Warrants.
Investors ratified Grassi & Co., CPAs, P.C. as auditor and approved an adjournment proposal, but did not approve an amendment to increase the share reserve under the 2023 Stock Incentive Plan.
Azitra, Inc. adjourned its 2026 annual meeting of stockholders after failing to reach a quorum. A quorum would have required shares representing 33 1/3% of the common stock entitled to vote, but only about 17% of eligible shares were represented by proxy.
The meeting, originally convened on June 4, 2026, will reconvene virtually on June 15, 2026, at 11:00 a.m. Eastern Time via www.proxydocs.com/AZTR. Stockholders of record as of April 24, 2026 remain entitled to vote, and previously submitted proxies remain valid unless changed.
Azitra’s press release explains that stockholders can vote or change prior votes by mail, internet, telephone, or during the reconvened virtual meeting, following instructions in the definitive proxy statement filed on May 8, 2026.